Amcor stock falls after Raymond James reiterates Market Perform rating
Meghan V. Joyce, a director at Guardant Health , Inc. (NASDAQ:GH), recently reported a sale of company shares according to a filing with the Securities and Exchange Commission (SEC). On June 13, 2025, Joyce sold 3,337 shares of Guardant Health common stock at a price of $47.22 per share, amounting to a total transaction value of $157,573. Following this sale, Joyce holds 11,150 shares directly. The transaction comes as the $6.1 billion healthcare company trades near its 52-week high of $52.92, having delivered an impressive 38.41% return over the past six months.
The filing also detailed a transaction on June 12, 2025, involving the acquisition of 6,674 shares through the vesting of restricted stock units. These shares were acquired at no cost, bringing Joyce’s total direct ownership to 14,487 shares before the subsequent sale. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 4.11, though current indicators suggest the stock may be slightly overvalued. Discover more insights with InvestingPro’s comprehensive analysis of GH and 1,400+ other stocks.
In other recent news, Guardant Health has made significant strides with its Shield multi-cancer detection (MCD) test, receiving the U.S. Food and Drug Administration’s (FDA) Breakthrough Device designation. This designation aims to expedite the development of medical devices that could improve the diagnosis of life-threatening diseases. The Shield test, which screens for multiple cancer types in individuals aged 45 and older, was also selected by the National Cancer Institute for the Vanguard Study due to its strong performance in cancer detection. Additionally, Guardant Health presented clinical validation data at the American Society for Clinical Oncology Annual Meeting, demonstrating the test’s high specificity and sensitivity.
Analyst firms have responded positively to these developments. Mizuho (NYSE:MFG) raised its price target for Guardant Health to $65, citing an optimistic outlook for the Shield test. UBS analysts reiterated a Buy rating with a $70 price target, highlighting Guardant Health’s leadership in tumor profiling and promising opportunities in cancer screening. Leerink Partners also maintained an Outperform rating and a $65 price target, noting the company’s strong position in the diagnostics market. These recent developments underscore Guardant Health’s potential for growth and innovation in the healthcare sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.